These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 27846839)

  • 1. Combination therapy only shows short-term superiority over monotherapy on ureteral stent-related symptoms - outcome from a randomized controlled trial.
    Liu Q; Liao B; Zhang R; Jin T; Zhou L; Luo D; Liu J; Li H; Wang K
    BMC Urol; 2016 Nov; 16(1):66. PubMed ID: 27846839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of solifenacin, as monotherapy or combination with tamsulosin in ureteral stent-related symptoms: a systematic review and meta-analysis.
    Wang J; Zhang X; Zhang T; Mu J; Bai B; Lei Y
    World J Urol; 2017 Nov; 35(11):1669-1680. PubMed ID: 28550362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A critical assessment of the effects of tamsulosin and solifenacin as monotherapies and as a combination therapy for the treatment of ureteral stent-related symptoms: a 2 × 2 factorial randomized trial.
    Park J; Yoo C; Han DH; Shin DW
    World J Urol; 2015 Nov; 33(11):1833-40. PubMed ID: 25809877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial comparing alpha blocker (tamsulosin) and anticholinergic (solifenacin) in treatment of ureteral stent-related symptoms.
    El-Nahas AR; Tharwat M; Elsaadany M; Mosbah A; Gaballah MA
    World J Urol; 2016 Jul; 34(7):963-8. PubMed ID: 26453222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).
    Van Kerrebroeck P; Haab F; Angulo JC; Vik V; Katona F; Garcia-Hernandez A; Klaver M; Traudtner K; Oelke M
    Eur Urol; 2013 Sep; 64(3):398-407. PubMed ID: 23537687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamsulosin Monotherapy Is Effective in Reducing Ureteral Stent-related Symptoms: A Meta-analysis of Randomized Controlled Studies.
    Chen YB; Gao L; Jiang Q; Ran K; Luo RT
    Curr Med Sci; 2019 Oct; 39(5):707-718. PubMed ID: 31612387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cost-effectiveness model of a fixed dose combination of solifenacin and tamsulosin for the treatment of LUTS associated with BPH with inadequate response to monotherapy.].
    Alcántara A; Cózar JM; Errando C; Rubio-Rodríguez D; Rubio-Rodríguez D; Rubio-Terrés C; Mora AM; Duran A
    Arch Esp Urol; 2018 Sep; 71(7):595-606. PubMed ID: 30198851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamsulosin, Solifenacin, and Their Combination for the Treatment of Stent-Related Symptoms: A Randomized Controlled Study.
    Dellis AE; Papatsoris AG; Keeley FX; Bamias A; Deliveliotis C; Skolarikos AA
    J Endourol; 2017 Jan; 31(1):100-109. PubMed ID: 27809592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial.
    van Kerrebroeck P; Chapple C; Drogendijk T; Klaver M; Sokol R; Speakman M; Traudtner K; Drake MJ;
    Eur Urol; 2013 Dec; 64(6):1003-12. PubMed ID: 23932438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does Combination Therapy with Tamsulosin and Tolterodine Improve Ureteral Stent Discomfort Compared with Tamsulosin Alone? A Double-Blind, Randomized, Controlled Trial.
    Sivalingam S; Streeper NM; Sehgal PD; Sninsky BC; Best SL; Nakada SY
    J Urol; 2016 Feb; 195(2):385-90. PubMed ID: 26393904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solifenacin and Tamsulosin Combination Therapy Decreases Urine Nerve Growth Factor/Creatinine Levels in Men.
    Chan R; Munoz A; Wenker EP; Whipple M; Miles B; Boone TB
    Urology; 2016 May; 91():150-3. PubMed ID: 26829718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms.
    Lee HN; Lee KS; Kim JC; Chung BH; Kim CS; Lee JG; Kim DK; Park CH; Park JK; Hong SJ
    Int J Clin Pract; 2015 Apr; 69(4):444-53. PubMed ID: 25363606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind, placebo-controlled trial to compare solifenacin versus trospium chloride in the relief of double-J stent-related symptoms.
    Abdelhamid MH; Zayed AS; Ghoneima WE; Elmarakbi AA; El Sheemy MS; Aref A; Abdelbary A; Nour HH
    World J Urol; 2017 Aug; 35(8):1261-1268. PubMed ID: 28050642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A Crossover Comparison Study on Lower Urinary Tract Symptoms with Overactive Bladder Secondary to Benign Prostatic Hyperplasia: Naftopidil versus Tamsulosin with Solifenacin].
    Utsunomiya N; Matsumoto K; Tsunemori H; Muguruma K; Kawakita M; Kamiyama Y; Kanamaru S; Ito N; Tsukazaki H; Shirahase T; Takahashi T
    Hinyokika Kiyo; 2016 Jul; 62(7):341-7. PubMed ID: 27569351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with tamsulosin and solifenacin for male lower urinary tract symptoms with predominant filling symptoms: a new approach to an old problem.
    Angulo JC
    Curr Med Res Opin; 2015 Nov; 31(11):1963-5. PubMed ID: 26368336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolving picture of lower urinary tract symptom management.
    Tubaro A; De Nunzio C; Puccini F; Presicce F
    Eur Urol; 2015 Feb; 67(2):271-2. PubMed ID: 25457016
    [No Abstract]   [Full Text] [Related]  

  • 17. Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy.
    Lee YJ; Huang KH; Yang HJ; Chang HC; Chen J; Yang TK
    Urolithiasis; 2013 Jun; 41(3):247-52. PubMed ID: 23515684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tamsulosin, oxybutynin or their combination in the treatment of ureteral stent-related symptoms].
    Maldonado-Alcaraz E; Moreno-Palacios J; López-Sámano VA; Landa-Salas JD; Torres-Mercado LO; García-Cruz C
    Rev Med Inst Mex Seguro Soc; 2017; 55(5):568-574. PubMed ID: 29193937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.
    Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W
    J Urol; 2009 Dec; 182(6):2825-30. PubMed ID: 19837435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.